BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

C:\Program Files\Stnexp\Queries\10030186.str





chain nodes :
1 2 4 7 8 9 10 16
ring nodes :
11 12 13 14 15
ring/chain nodes :
17
chain bonds :
1-2 2-4 4-7 7-8 7-9 9-12 9-10 15-16 16-17
ring bonds :
11-12 11-15 12-13 13-14 14-15
exact/norm bonds :
1-2 2-4 4-7 7-8 7-9 9-12 9-10 11-12 11-15 12-13 13-14 14-15 16-17
exact bonds :
15-16

G1:C,O,S,N

G2:C,N

Match level :
1:Atom 2:CLASS 4:CLASS 7:CLASS 8:Atom 9:CLASS 10:CLASS 11:Atom 12:Atom 13:Atom
14:Atom 15:Atom 16:CLASS 17:CLASS

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1611hxl

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  AUG 05   New pricing for EUROPATFULL and PCTFULL effective
                   August 1, 2003
 NEWS  5  AUG 13   Field Availability (/FA) field enhanced in BEILSTEIN
 NEWS  6  AUG 18   Data available for download as a PDF in RDISCLOSURE
 NEWS  7  AUG 18   Simultaneous left and right truncation added to PASCAL
 NEWS  8  AUG 18   FROSTI and KOSMET enhanced with Simultaneous Left and Righ
                   Truncation
 NEWS  9  AUG 18   Simultaneous left and right truncation added to ANABSTR
 NEWS 10  SEP 22   DIPPR file reloaded
 NEWS 11  SEP 25   INPADOC: Legal Status data to be reloaded
 NEWS 12  SEP 29   DISSABS now available on STN
 NEWS 13  OCT 10   PCTFULL: Two new display fields added
 NEWS 14  OCT 21   BIOSIS file reloaded and enhanced

 NEWS EXPRESS  OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:59:59 ON 23 OCT 2003

=> fil reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21
```

FILE 'REGISTRY' ENTERED AT 13:00:13 ON 23 OCT 2003

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 OCT 2003 HIGHEST RN 608090-08-0
DICTIONARY FILE UPDATES: 22 OCT 2003 HIGHEST RN 608090-08-0

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10030186.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

G2 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:00:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 31555 TO ITERATE

```
  3.2% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:       620500 TO   641700
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=>
Uploading 10030186.str

L3      STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3             STR
```




```
G1 C,O,S,N
G2 C,N


Structure attributes must be viewed using STN Express query preparation.


=> s l3
SAMPLE SEARCH INITIATED 13:03:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  31555 TO ITERATE

  3.2% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:       620500 TO   641700
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L3

=>
```

Uploading 10030186.str

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 C,O,S,N

G2 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 13:04:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1348 TO ITERATE

74.2% PROCESSED 1000 ITERATIONS 6 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 24758 TO 29162
PROJECTED ANSWERS: 6 TO 331

L6 6 SEA SSS SAM L5

=> d scan

L6 6 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-2-oxo-1-phenyl-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]-, monohydrochloride (9CI)
MF C28 H33 Cl N4 O2 . Cl H

Absolute stereochemistry.



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

```
=>
Uploading 10030186.str

L7      STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7              STR
```




```
G1 C,O,S,N
G2 C,N


Structure attributes must be viewed using STN Express query preparation.


=> s l7
SAMPLE SEARCH INITIATED 13:05:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2446 TO ITERATE

 40.9% PROCESSED    1000 ITERATIONS                                 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        45954 TO    51886
PROJECTED ANSWERS:               2 TO      229

L8             2 SEA SSS SAM L7

=> s l7 ful
FULL SEARCH INITIATED 13:05:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  47362 TO ITERATE

100.0% PROCESSED   47362 ITERATIONS                              67 ANSWERS
SEARCH TIME: 00.00.02

L9            67 SEA SSS FUL L7

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

FULL ESTIMATED COST 151.35 151.56

FILE 'CAPLUS' ENTERED AT 13:05:31 ON 23 OCT 2003

FILE COVERS 1907 - 23 Oct 2003 VOL 139 ISS 17
FILE LAST UPDATED: 22 Oct 2003 (20031022/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l9
L10 9 L9

=> d abs ibib hitstr 1-
YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y

L10 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II

AB The invention discloses novel peptides I [Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino, or heterocycloalkylamino; R1 is acyl; Z is selected from O, N, CH or CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halo, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; W, Q, G, J, L, M independently may be present or absent; W is CO, CS, C(:N-CN), or SO2; Q is CH, N, P, alkylidene, O, NR, S, or SO2; A is O, CH, alkylidene, NR, S, SO2, or a bond; E is CH, N, alkylidene, or a double bond; G is alkylidene; J is alkylidene, SO2, NH, NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO2, or alkylidene (with provisos)] which have HCV protease inhibitory activity as well as methods for prepg. such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders assocd. with the HCV protease. Thus, peptide II was prepd. and showed Ki = 1-100 nM (category A) in the HCV continuous assay.

ACCESSION NUMBER: 2003:591204 CAPLUS
DOCUMENT NUMBER: 139:149928
TITLE: Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhn, Viyyoor M.; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen,

Stephane L.; Chan, Tin-yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, George F.; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Wong, Jesse K.; Nair, Latha G.

PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.
SOURCE: PCT Int. Appl., 633 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062265	A2	20030731	WO 2003-US1430	20030116

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-52386 A 20020118
OTHER SOURCE(S): MARPAT 139:149928

IT **394722-91-9P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394722-91-9 CAPLUS
CN Glycinamide, (2S)-N-(2-carboxybenzoyl)-2-cyclohexylglycyl-(4S)-4-[[(3-phenoxybenzoyl)amino]methyl]-L-prolyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CO2H
O
N
H
S
O
N
S
S
O
O
N
H
Pr-n
O
N
H
H
N
S
O
NH2
Ph
NH
PhO
O

L10 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I

AB Compds. I [R1 = (un)substituted Ph, pyridyl, pyrimidyl, pyridazinyl, furyl, thienyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, naphthyl, benzofuryl, benzothienyl, quinolyl, isoquinolyl, piperidinyl, tetrahydropyranyl, or (cyclo)alkyl; R2 = 4-Cl-, 4-MeO-, or 4-MeC6H4 which may be 3-substituted, 2- or 6-indolyl which may be 5- or 3-substituted, resp., or 2-benzothienyl which may be 6-substituted; R3 = (un)substituted 4-pyridyl or 4-pyrimidinyl, 3-pyridazinyl; R4 = H or Me] or their pharmaceutically-acceptable salts were prepd. as factor Xa inhibitors useful in the treatment of thrombotic disorders. Thus, 1-[4-methoxybenzoyl-DL-(2-chlorophenyl)glycinyl]-4-[[(2-methoxypyrimidin-4-yl)(methyl)amino]methyl]piperidine was prepd. by coupling of tert-butoxycarbonyl-DL-(2-chlorophenyl)glycine with 4-[[(2-methoxypyrimidin-4-yl)(methyl)amino]methyl]piperidine hydrochloride, followed by deprotection and acylation with anisic acid.

ACCESSION NUMBER: 2003:472387 CAPLUS
DOCUMENT NUMBER: 139:53306
TITLE: Preparation of amino acid piperidinamide derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders
INVENTOR(S): Hiscock, Steven Douglas; Jones, Stuart Donald; Sall, Daniel Jon; Young, Stephen Clinton; Wiley, Michael Robert
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049737	A1	20030619	WO 2002-US36149	20021209

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-339324P P 20011212

OTHER SOURCE(S): MARPAT 139:53306

IT **544695-85-4P 544695-86-5P 544695-87-6P**
544695-88-7P 544695-89-8P 544695-90-1P
544695-91-2P 544695-92-3P 544695-93-4P
544695-94-5P 544695-95-6P 544695-96-7P
544695-97-8P 544695-98-9P 544695-99-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid piperidinamide derivs. as factor Xa inhibitors for treatment of thrombotic disorders)

RN 544695-85-4 CAPLUS

CN Benzamide, N-[1-(2-chlorophenyl)-2-[4-[[(2-methoxy-4-pyrimidinyl)methylamino]methyl]-1-piperidinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 544695-86-5 CAPLUS

CN Benzamide, N-[1-(2-chlorophenyl)-2-[4-[(methyl-4-pyrimidinylamino)methyl]-1-piperidinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 544695-87-6 CAPLUS

CN Benzamide, N-[1-(2-chlorophenyl)-2-[4-[[(2-cyano-4-pyridinyl)methylamino]methyl]-1-piperidinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 544695-88-7 CAPLUS
CN Benzamide, N-[1-(2-chlorophenyl)-2-[4-[[methyl[2-(trifluoromethyl)-4-pyridinyl]amino]methyl]-1-piperidinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 544695-89-8 CAPLUS
CN 1H-Indole-6-carboxamide, N-[2-[4-[(methyl-4-pyridinylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)



RN 544695-90-1 CAPLUS
CN 1H-Indole-6-carboxamide, N-[2-oxo-1-phenyl-2-[4-[(4-pyridinylamino)methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 544695-91-2 CAPLUS
CN Benzamide, N-[1-(2-chlorophenyl)-2-[4-[(methyl-4-pyridinylamino)methyl]-1-piperidinyl]-2-oxoethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 544695-92-3 CAPLUS
CN Benzamide, 4-methoxy-N-[1-(2-methoxyphenyl)-2-[4-[(methyl-4-pyridinylamino)methyl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 544695-93-4 CAPLUS
CN Benzamide, N-[1-[2-(difluoromethoxy)phenyl]-2-[4-[(methyl-4-pyridinylamino)methyl]-1-piperidinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 544695-94-5 CAPLUS
CN Benzamide, N-[1-(2-chlorophenyl)-2-oxo-2-[4-[(4-pyrimidinylamino)methyl]-1-piperidinyl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 544695-95-6 CAPLUS
CN Benzamide, N-[1-(2-chlorophenyl)-2-oxo-2-[4-[(3-pyridazinylamino)methyl]-1-piperidinyl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 544695-96-7 CAPLUS
CN Benzamide, N-[1-(2-chlorophenyl)-2-[4-[(methyl-3-pyridazinylamino)methyl]-1-piperidinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 544695-97-8 CAPLUS
CN Benzamide, 4-methoxy-N-[2-oxo-2-[4-[(4-pyridinylamino)methyl]-1-piperidinyl]-1-[2-(trifluoromethyl)phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 544695-98-9 CAPLUS
CN Benzamide, 4-methoxy-N-[2-[4-[(methyl-4-pyridinylamino)methyl]-1-piperidinyl]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 544695-99-0 CAPLUS
CN Benzamide, N-[1-(2-chlorophenyl)-2-oxo-2-[4-[(4-pyridinylamino)methyl]-1-piperidinyl]ethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I

AB Title compds. I [R1, R2 = H, OH, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl, cycloalkyl; R3 = R1, R2, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulfonyl, alkylsulfenyl, alkylsulfonamido, alkylaminosulfonyl, haloalkoxy, haloalkyl; X = C, N, O, S, CO, CR1, C(R1)2, NR1 with at least one X being C, CO, CR1 or C(R1)2, with the proviso that if the benzamidine group is unsubstituted and the X-X group is -CH2C(R1)2-, then R1 = H or attached to the alkylene carbon atom by a heteroatom; L = org. linker contg. 1-5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Y = N, CR1; YL = cyclic group; Cy = (un)satd., (poly)cyclic, (hetero)cyclic group optionally substituted by groups R3 or Ph optionally substituted by R3; Lp = lipophilic alkyl, heterocyclic, alkenyl, alkaryl, (poly)cycloalkyl, cycloalkenyl, aryl, aralkyl, haloalkyl, or a combination of two or more such groups optionally substituted by oxa, oxo, aza, thio, halo, amino, hydroxy or by R3; D = H bond donor group; n = 0-2], or corresponding compds. in which the (un)substituted amidino group R1R2NC(:NR1) is replaced with an (un)substituted aminomethyl group, or their physiol. tolerable salts were prepd. as serine protease inhibitors useful as antithrombotic agents. 3-Amidino- and 3-(aminomethyl)benzoyl-D-phenylglycine 4-aminomethylcyclohexylmethylamide are among 190 compds. synthesized.

ACCESSION NUMBER: 2002:354079 CAPLUS
DOCUMENT NUMBER: 136:355487
TITLE: Preparation of meta-benzamidine derivatives of amino acids or dipeptides as serine protease inhibitors
INVENTOR(S): Liebeschuetz, John Walter; Wylie, William Alexander; Waszkowycz, Bohdan; Murray, Christopher William; Rimmer, Andrew David; Welsh, Pauline Mary; Jones, Stuart Donald; Roscoe, Jonathan Michael Ernest; Young, Stephen Clinton; Morgan, Phillip John
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. Ser. No. 485,678.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2002055522 A1 20020509 US 2001-988082 20011119
WO 9911658 A1 19990311 WO 1998-GB2605 19980828
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO 2000077027 A2 20001221 WO 2000-GB2291 20000613
WO 2000077027 A3 20010525
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: GB 1997-18392 A 19970829
GB 1998-3173 A 19980213
WO 1998-GB2605 W 19980828
GB 1999-13823 A 19990614
US 1999-142064P P 19990702
US 2000-485678 A2 20000225
WO 2000-GB2291 A2 20000613
GB 1999-18741 A 19990809
GB 1999-29552 A 19991214
GB 1999-29553 A 19991214
OTHER SOURCE(S): MARPAT 136:355487
IT **221233-09-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of meta-benzamidine derivs. of amino acids or dipeptides as serine protease inhibitors)
RN 221233-09-6 CAPLUS
CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-[4-(aminomethyl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II

AB Peptides I were prepd. wherein Y is alkyl, alkyl-aryl, heteroaryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy,, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino and heterocycloalkylamino; R1 is acyl, borate; Z is selected from O, N, CH or CR; W, Q, G, J, L, M independently maybe present or absent; W is C=O, C=S, C(=N-CN), or SO; Q is CH, N, P, alkylidene, O, amine,S, or SO; A is O, CH, alkylidene, amine, S, SO or bond; E is CH, N, alkylidene, or double bond; G is alkylidene; J is alkylidene, SO, NH, NR, O; L is CH, alkylidene, O, S or NR; M is O, NR,S, SO, alkylidene; p is 0 to 6; and R-R4 are independently selected from the group consisting of H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halogen; (cycloalkyl)alkyl and (heterocycloalkyl)alkyl, which have HCV protease inhibitory activity as well as methods for prepg. such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders assocd. with the HCV protease. Thus peptide II was prepd. and tested as antiviral agent and NS3-serine protease inhibitors of hepatitis C virus with Ki ranges in category A = 1-100 nM; category B = 101-1,000 nM; category C > 1000 nM. Also disclosed is the use of I for the manuf. of a medicament for treating HCV, AIDS, and related disorders.

ACCESSION NUMBER: 2002:90062 CAPLUS
DOCUMENT NUMBER: 136:167698
TITLE: Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-Tsung; Zhu, Zhaoning; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal N.; Ganguly, Ashit K.; Chen, Kevin X.;

Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.

PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.
SOURCE: PCT Int. Appl., 536 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008244	A2	20020131	WO 2001-US22678	20010719
WO 2002008244	A3	20030619		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001076988	A5	20020205	AU 2001-76988	20010719
BR 2001012540	A	20030624	BR 2001-12540	20010719
NO 2003000272	A	20030321	NO 2003-272	20030120

PRIORITY APPLN. INFO.: US 2000-220108P P 20000721
WO 2001-US22678 W 20010719

OTHER SOURCE(S): MARPAT 136:167698

IT **394722-91-9P 394728-91-7P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394722-91-9 CAPLUS

CN Glycinamide, (2S)-N-(2-carboxybenzoyl)-2-cyclohexylglycyl-(4S)-4-[[(3-phenoxybenzoyl)amino]methyl]-L-prolyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394728-91-7 CAPLUS
CN Glycinamide, (2S)-N-(2-carboxybenzoyl)-2-cyclohexylglycyl-(4S)-4-[[(4-phenoxybenzoyl)amino]methyl]-L-prolyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AB Compds. R2-X-X-Y(Cy)-L-Lp(D)n [R2 is a 5- or 6-membered arom. carbon ring optionally interrupted by a N, O or S ring atom, optionally substituted at the 3 and/or 4 position or forms a fused ring system at these positions, which is an optionally substituted 5- or 6-membered carbocyclic or heterocyclic ring, or substituted at the position alpha to X-X; X is a C, N, O or S atom or a CO, CR1a, C(R1a)2 or NR1a group, where R1a represents H, OH, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by OH, alkylamino, alkoxy, oxo, aryl or cycloalkyl; Y is a N atom or a CR1b group (R1b defined as for R1a); Cy is an (un)substituted, (un)satd., mono- or polycyclic, homo- or heterocyclic group; -L-Lp(D)n is 3-(Rq-CH2)-1-pyrrolidinylcarbonyl or 4-(Rq-CH2)-1-piperidinylcarbonyl, where Rq is an amino group] or their physiol.-tolerable salts were prepd. for use as serine protease and factor Xa inhibitors in the treatment of cardiovascular disorders. Compds. of the invention were found to significantly elongate the partial thromboplastin time (prothrombin time). Thus, 1-[(4-methoxybenzoyl-D-phenylglycinyl)]-4-[(isopropylamino)methyl]piperidine hydrochloride was prepd. in the first of 28 examples.

ACCESSION NUMBER: 2001:923766 CAPLUS
DOCUMENT NUMBER: 136:54019
TITLE: Preparation of amino acid derivatives as serine protease inhibitors
INVENTOR(S): Liebeschuetz, John Walter; Murray, Christopher William; Young, Stephen Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Wylie, William Alexander; Masters, John Joseph; Wiley, Michael Robert; Sheehan, Scott Martin; Engel, David Birenbaum; Watson, Brian Morgan
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096304	A1	20011220	WO 2001-GB2572	20010612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2000076971	A2	20001221	WO 2000-GB2302	20000613
WO 2000076971	A3	20010802		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1289953 A1 20030312 EP 2001-938403 20010612

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2002151724 A1 20021017 US 2002-30186 20020204

PRIORITY APPLN. INFO.: WO 2000-GB2302 W 20000613
GB 2000-30306 A 20001213
GB 1999-13823 A 19990614
US 1999-142064P P 19990702
GB 1999-18741 A 19990809
GB 1999-29553 A 19991214
WO 2001-GB2572 W 20010612

OTHER SOURCE(S): MARPAT 136:54019

IT **381215-62-9P 381215-64-1P 381215-66-3P**
381215-68-5P 381215-70-9P 381215-78-7P
381216-25-7P 381216-33-7P 381216-34-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of amino acid derivs. as serine protease inhibitors)

RN 381215-62-9 CAPLUS

CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[[(1-methylethyl)amino]methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381215-61-8
CMF C26 H32 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 381215-64-1 CAPLUS

CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381215-63-0
CMF C27 H32 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 381215-66-3 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[(diethylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381215-65-2
CMF C27 H34 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 381215-68-5 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381215-67-4
CMF C28 H34 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 381215-70-9 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[(4-hydroxy-1-piperidinyl)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 381215-69-6
CMF C28 H34 N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 381215-78-7 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[[(3R)-3-(hydroxymethyl)-1-pyrrolidinyl]methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 381215-77-6
CMF C28 H34 N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 381216-25-7 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-[(cyclohexylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381216-33-7 CAPLUS
CN Benzamide, 4-methoxy-N-[1-(2-methoxyphenyl)-2-oxo-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 381216-34-8 CAPLUS
CN 1H-Indole-6-carboxamide, N-[1-(2-methoxyphenyl)-2-oxo-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



IT **313489-01-9P 313489-02-0P 313489-03-1P**
313489-04-2P 313489-05-3P 381215-67-4P
381215-72-1P 381215-74-3P 381215-76-5P
381215-80-1P 381215-82-3P 381215-83-4P
381215-84-5P 381215-86-7P 381215-88-9P
381215-90-3P 381215-92-5P 381215-94-7P
381215-96-9P 381215-98-1P 381216-00-8P
381216-02-0P 381216-04-2P 381216-06-4P
381216-08-6P 381216-10-0P 381216-12-2P
381216-14-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid derivs. as serine protease inhibitors)

RN 313489-01-9 CAPLUS
CN Benzamide, 4-methoxy-N-[(1R)-2-[4-[[(1-methylethyl)amino]methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 313489-02-0 CAPLUS
CN Benzamide, N-[(1R)-2-[4-[(dimethylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-03-1 CAPLUS
CN Benzamide, N-[(1R)-2-[4-[(diethylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 313489-04-2 CAPLUS
CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-05-3 CAPLUS
CN Benzamide, N-[(1R)-2-[4-[(2,5-dihydro-1H-pyrrol-1-yl)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 381215-67-4 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381215-72-1 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(1-piperazinylmethyl)-1-piperidinyl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381215-71-0
CMF C27 H33 N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 381215-74-3 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[(4-methyl-1-piperazinyl)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381215-73-2
CMF C28 H35 N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 381215-76-5 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[(3-hydroxy-1-pyrrolidinyl)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 381215-75-4
CMF C27 H32 N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 381215-80-1 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[[(3S)-3-(hydroxymethyl)-1-pyrrolidinyl]methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 381215-79-8
CMF C28 H34 N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 381215-82-3 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[[4-(hydroxymethyl)-1-piperidinyl]methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 381215-81-2
CMF C29 H36 N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 381215-83-4 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-oxo-1-phenyl-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 381215-84-5 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-[(3-hydroxy-1-piperidinyl)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381215-86-7 CAPLUS
CN 1H-Indole-6-carboxamide, 3-methyl-N-[(1R)-2-oxo-1-phenyl-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 381215-88-9 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-2-oxo-1-phenyl-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 381215-90-3 CAPLUS
CN Benzamide, 4-methoxy-N-[1-(2-methoxyphenyl)-2-oxo-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 381215-92-5 CAPLUS
CN 1H-Indole-6-carboxamide, N-[1-(2-methoxyphenyl)-2-oxo-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 381215-94-7 CAPLUS
CN Benzamide, 4-methoxy-N-[2-oxo-2-[4-(1-piperidinylmethyl)-1-piperidinyl]-1-(5-thiazolyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 381215-96-9 CAPLUS
CN Benzamide, N-[1-(2-amino-4-thiazolyl)-2-oxo-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 381215-98-1 CAPLUS
CN Benzamide, 4-methoxy-N-[1-(2-methyl-4-thiazolyl)-2-oxo-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 381216-00-8 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-[(cyclohexylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 381216-02-0 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-[(4-pyridinylamino)methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381216-04-2 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[[(1-methylethyl)amino]methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 381216-06-4 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



● HCl

RN 381216-08-6 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[(diethylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 381216-10-0 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(1-piperidinylmethyl)-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 381216-12-2 CAPLUS

CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[(4-hydroxy-1-piperidinyl)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 381216-14-4 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[[(3R)-3-(hydroxymethyl)-1-pyrrolidinyl]methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **381216-32-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of amino acid derivs. as serine protease inhibitors)
RN 381216-32-6 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-[(cyclohexylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AB Compds. R2-X-X-Y(Cy)-L-Lp(D)n [R2 represents a 5- or 6-membered arom. carbon ring optionally interrupted by a N, O or S ring atom, optionally substituted at the 3 and/or 4 position or forms a fused ring system at these positions, which is an optionally substituted 5 or 6 membered carbocyclic or heterocyclic ring or substituted at the position alpha to X-X; X is a C, N, O or S atom or a CO, CR1a, C(R1a)2 or NR1a group, where R1a represents H, OH, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by OH, alkylamino, alkoxy, oxo, aryl or cycloalkyl; L is an org. linker group contg. 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Y is a N atom or a CR1b group (R1b defined as for R1a); Cy is an (un)substituted, (un)satd., mono- or polycyclic, homo- or heterocyclic group; Lp is a lipophilic org. group; D is a hydrogen bond donor group; n = 0-2] were prepd. for use as serine protease inhibitors. Compds. of the invention were found to significantly elongate the partial thromboplastin time (prothrombin time). Thus, 1-(3-amino-2-naphthoyl-D-phenylglycinyl)-4,4'-bispiperidine was prepd. and shown to double the prothrombin time at a concn. of 26 .mu.M.

ACCESSION NUMBER: 2000:900614 CAPLUS
DOCUMENT NUMBER: 134:56958
TITLE: Preparation of amino acid derivatives as serine protease inhibitors
INVENTOR(S): Liebeschuetz, John Walter; Lyons, Amanda Jane; Murray, Christopher William; Rimmer, Andrew David; Young, Stephen Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Morgan, Phillip John; Richards, Simon James; Wylie, William Alexander; Masters, John Joseph; Wiley, Michael Robert
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Protherics Molecular Design Limited
SOURCE: PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076971	A2	20001221	WO 2000-GB2302	20000613
WO 2000076971	A3	20010802		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000054140	A5	20010102	AU 2000-54140	20000613
EP 1192132	A2	20020403	EP 2000-938916	20000613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003502314	T2	20030121	JP 2001-503831	20000613
WO 2001096296	A1	20011220	WO 2001-GB2541	20010612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001096303 A1 20011220 WO 2001-GB2551 20010612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001096323 A1 20011220 WO 2001-GB2553 20010612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001096304 A1 20011220 WO 2001-GB2572 20010612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1289972 A1 20030312 EP 2001-936686 20010612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EP 1289950 A1 20030312 EP 2001-938386 20010612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EP 1289953 A1 20030312 EP 2001-938403 20010612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EP 1289954 A1 20030312 EP 2001-940716 20010612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001011451 A 20030624 BR 2001-11451 20010612
US 2002151724 A1 20021017 US 2002-30186 20020204
US 2003078438 A1 20030424 US 2002-30189 20020204
US 2003109706 A1 20030612 US 2002-30188 20020204
NO 2002005665 A 20021125 NO 2002-5665 20021125

PRIORITY APPLN. INFO.:
GB 1999-13823 A 19990614
US 1999-142064P P 19990702
GB 1999-18741 A 19990809
GB 1999-29553 A 19991214
WO 2000-GB2302 A 20000613
GB 2000-30303 A 20001213

	GB 2000-30304	A	20001213
	GB 2000-30305	A	20001213
	GB 2000-30306	A	20001213
	WO 2001-GB2541	W	20010612
	WO 2001-GB2551	W	20010612
	WO 2001-GB2553	W	20010612
	WO 2001-GB2572	W	20010612

OTHER SOURCE(S): MARPAT 134:56958

IT **313489-01-9P 313489-02-0P 313489-03-1P**
313489-04-2P 313489-05-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid derivs. as serine protease inhibitors)

RN 313489-01-9 CAPLUS

CN Benzamide, 4-methoxy-N-[(1R)-2-[4-[[(1-methylethyl)amino]methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 313489-02-0 CAPLUS

CN Benzamide, N-[(1R)-2-[4-[(dimethylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-03-1 CAPLUS

CN Benzamide, N-[(1R)-2-[4-[(diethylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 313489-04-2 CAPLUS
CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-05-3 CAPLUS
CN Benzamide, N-[(1R)-2-[4-[(2,5-dihydro-1H-pyrrol-1-yl)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L10 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AB Compds. R2-X-X-Y(Cy)-L-Lp(D)n [R2 represents a 5- or 6-membered arom. carbon ring optionally interrupted by a N, O or S ring atom, optionally substituted at the 3 and/or 4 position or forms a fused ring system at these positions, which is an optionally substituted 5 or 6 membered carbocyclic or heterocyclic ring; X is a C, N, O or S atom or a CO, CR1a, C(R1a)2 or NR1a group, where R1a represents H, OH, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by OH, alkylamino, alkoxy, oxo, aryl or cycloalkyl; L is an org. linker group contg. 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Y is a N atom or a CR1b group (R1b defined as for R1a); Cy is an (un)substituted, (un)satd., mono- or polycyclic, homo- or heterocyclic group; Lp is a lipophilic org. group; D is a hydrogen bond donor group; n = 0-2] were prepd. for use as serine protease inhibitors. Compds. of the invention were found to significantly elongate the partial thromboplastin time (prothrombin time). Thus, 1-(3-amino-2-naphthoyl-D-phenylglycinyl)-4,4'-bispiperidine was prepd. and shown to double the prothrombin time at a concn. of 26 .mu.M.

ACCESSION NUMBER: 2000:900613 CAPLUS
DOCUMENT NUMBER: 134:56957
TITLE: Preparation of amino acid derivatives as serine protease inhibitors
INVENTOR(S): Liebeschuetz, John Walter; Lyons, Amanda Jane; Murray, Christopher William; Rimmer, Andrew David; Young, Stephen Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Morgan, Phillip John; Richards, Simon James; Wylie, William Alexander; Lively, Sarah Elizabeth; Harrison, Martin James; Waszkowycz, Bohdan; Masters, John Joseph; Wiley, Michael John
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Protherics Molecular Design Limited
SOURCE: PCT Int. Appl., 350 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076970	A2	20001221	WO 2000-GB2296	20000613
WO 2000076970	A3	20010719		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1192135	A2	20020403	EP 2000-938912	20000613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:

GB 1999-13823	A	19990614
US 1999-142064P	P	19990702
GB 1999-18741	A	19990809
GB 1999-29552	A	19991214
GB 1999-29553	A	19991214

WO 2000-GB2296 W 20000613

OTHER SOURCE(S): MARPAT 134:56957

IT **313489-01-9P 313489-02-0P 313489-03-1P**
313489-04-2P 313489-05-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid derivs. as serine protease inhibitors)

RN 313489-01-9 CAPLUS

CN Benzamide, 4-methoxy-N-[(1R)-2-[4-[[(1-methylethyl)amino]methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 313489-02-0 CAPLUS

CN Benzamide, N-[(1R)-2-[4-[(dimethylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-03-1 CAPLUS

CN Benzamide, N-[(1R)-2-[4-[(diethylamino)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 313489-04-2 CAPLUS
CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-05-3 CAPLUS
CN Benzamide, N-[(1R)-2-[4-[(2,5-dihydro-1H-pyrrol-1-yl)methyl]-1-piperidinyl]-2-oxo-1-phenylethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L10 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II

AB Title compds. I [R1, R2 = H, OH, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl, cycloalkyl; R3 = R1, R2, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulfonyl, alkylsulfenyl, alkylsulfonamido, alkylaminosulfonyl, haloalkoxy, haloalkyl; X = C, N, O, S, CO, CR1, C(R1)2, NR1 with at least one X being C, CO, CR1 or C(R1)2, with the proviso that if the benzamidine group is unsubstituted and the X-X group is -CH2C(R1)2-, then R1 = H or attached to the alkylene carbon atom by a heteroatom; L = org. linker contg. 1-5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Y = N, CR1; YL = cyclic group; Cy = (un)satd., (poly)cyclic, (hetero)cyclic group optionally substituted by groups R3 or Ph optionally substituted by R3; Lp = lipophilic alkyl, heterocyclic, alkenyl, alkaryl, (poly)cycloalkyl, cycloalkenyl, aryl, aralkyl, haloalkyl, or a combination of two or more such groups optionally substituted by oxa, oxo, aza, thio, halo, amino, hydroxy or by R3; D = H bond donor group; n = 0-2] and their physiol. tolerable salts were prepd. as serine protease inhibitors useful as antithrombotic agents. Synthesis methodol. for prepg. some I was provided, and common starting materials were Fmoc- or Boc-(D)-phenylglycine and m-amidinobenzoic acid. Descriptions of enzyme assays were given, but no enzyme inhibition data was provided for I. To measure the antithrombotic activity, a partial thromboplastin time test assay was done, and for example, m-amidinobenzoyl-D-phenylglycine ester II (prepn. not given, but 1H NMR characterization data provided), at 1.9 .mu.M concn., doubled the clotting time.

ACCESSION NUMBER: 1999:184269 CAPLUS
DOCUMENT NUMBER: 130:237884
TITLE: Preparation of meta-benzamidine derivatives of amino acids or dipeptides as serine protease inhibitors
INVENTOR(S): Liebeschuetz, John Walter; Wylie, William Alexander; Waszkowycz, Bohdan; Murray, Christopher William; Rimmer, Andrew David; Welsh, Pauline Mary; Jones,

Stuart Donald; Roscoe, Jonathan Michael Ernest; Young, Stephen Clinton; Morgan, Phillip John
PATENT ASSIGNEE(S): Proteus Molecular Design Ltd., UK
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911658	A1	19990311	WO 1998-GB2605	19980828
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9888757	A1	19990322	AU 1998-88757	19980828
EP 1009758	A1	20000621	EP 1998-940430	19980828
R: DE, FR, GB, IT				
US 2002055522	A1	20020509	US 2001-988082	20011119

PRIORITY APPLN. INFO.:
GB 1997-18392 A 19970829
GB 1998-3173 A 19980213
WO 1998-GB2605 W 19980828
GB 1999-13823 A 19990614
US 1999-142064P P 19990702
US 2000-485678 A2 20000225
WO 2000-GB2291 A2 20000613

OTHER SOURCE(S): MARPAT 130:237884

IT **221233-09-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of meta-benzamidine derivs. of amino acids or dipeptides as serine protease inhibitors)

RN 221233-09-6 CAPLUS

CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-[4-(aminomethyl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
GI



AB ArSO2AQ [Ar = (substituted) aryl, heterocyclyl; A = amino acid residue; Q = Q1, Q2; X = H, alkyl; Y = SO3H, PO(OR14)2, OH, SH, NR15R16, halo, (substituted) (CqH2q)Q3, etc.; Q3 = H, COR14, CO2R14, CONR15R16, SO3H, OR14, OCOR14, PO(OR14)2, NR15R16, SR14, halo; R14, R15, R16 = H, alkyl, cycloalkyl, aralkyl; R15R16N = 5-6 membered azacycloalkyl, oxazacycloalkyl; XY = O; Z = bond, O, N optionally substituted by X or Y; m, n = 2-4; m + n = 4-6, j, k = 0-2; j + k = 2-3; when A = Arg, then X, Y .noteq. alkyl; when Q = COR14, then q = 1-8], were prepd. Thus, (S)-arginine and 3-(1-methyl-1-phenylethyl)benzenesulfonyl chloride were stirred with Na2CO3 in H2O/dioxane to give 5-guanidino-2(S)-[3-(1-methyl-1-phenylethyl)benzenesulfonylamino]pentanoic acid. The latter was converted to the acid chloride hydrochloride, which was condensed with pyrrolidin-2(R)-ylmethanol in DMF contg. Et3N to give N-[4-guanidino-1(S)-2(R)-hydroxymethylpyrrolidine-1-carbonylbutyl]-3-(1-methyl-1-phenylethyl)benzenesulfonamide. Tested title compds. inhibited human .alpha.-thrombin with Ki = 0.007-0.094 .mu.M.

ACCESSION NUMBER: 1996:746209 CAPLUS
DOCUMENT NUMBER: 126:19324
TITLE: Preparation of arylsulfonylamino acid amide trypsin and thrombin inhibitors.
INVENTOR(S): Hoyle, William; Howarth, Graham Arton; Brundish, Derek Edward; Kane, Peter Daniel; Walker, Clive Victor; Hayler, Judy; Fullerton, Joseph David; Smith, Garric Paul; Wathey, William Bernard; et al.
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9629327	A1	19960926	WO 1996-GB520	19960308
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9648872	A1	19961008	AU 1996-48872	19960308
EP 815103	A1	19980107	EP 1996-904963	19960308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11502219	T2	19990223	JP 1996-528155	19960308
ZA 9602112	A	19960918	ZA 1996-2112	19960315

PRIORITY APPLN. INFO.: GB 1995-5538 19950318
WO 1996-GB520 19960308

OTHER SOURCE(S): MARPAT 126:19324

IT **184040-06-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylsulfonylamino acid amide trypsin and thrombin inhibitors)

RN 184040-06-0 CAPLUS

CN 4-Piperidineethanamine, 1-[benzo[b]thien-2-yl[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]acetyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 12:59:59 ON 23 OCT 2003)

     FILE 'REGISTRY' ENTERED AT 13:00:13 ON 23 OCT 2003
L1               STRUCTURE UPLOADED
L2             0 S L1
L3               STRUCTURE UPLOADED
L4             0 S L3
L5               STRUCTURE UPLOADED
L6             6 S L5
L7               STRUCTURE UPLOADED
L8             2 S L7
L9            67 S L7 FUL

     FILE 'CAPLUS' ENTERED AT 13:05:31 ON 23 OCT 2003
L10            9 S L9

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      41.24     192.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -5.86      -5.86

STN INTERNATIONAL LOGOFF AT 13:06:00 ON 23 OCT 2003
```

species of WO 99/11657

10/23/2003 Print selected from Online session

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611hxl

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS	9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	10	SEP 22	DIPPR file reloaded
NEWS	11	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS	12	SEP 29	DISSABS now available on STN
NEWS	13	OCT 10	PCTFULL: Two new display fields added
NEWS	14	OCT 21	BIOSIS file reloaded and enhanced

NEWS EXPRESS	OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:57:07 ON 23 OCT 2003

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 08:57:14 ON 23 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Oct 2003 VOL 139 ISS 17
FILE LAST UPDATED: 22 Oct 2003 (20031022/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s wo9911657/pn
L1 1 WO9911657/PN

=> select L1 rn 1-
E1 THROUGH E133 ASSIGNED

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.22	2.43

FILE 'REGISTRY' ENTERED AT 08:57:48 ON 23 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 OCT 2003 HIGHEST RN 608090-08-0
DICTIONARY FILE UPDATES: 22 OCT 2003 HIGHEST RN 608090-08-0

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

```
=> s e1-e133
             1 102089-74-7/BI
               (102089-74-7/RN)
             1 104-84-7/BI
               (104-84-7/RN)
             1 105-36-2/BI
               (105-36-2/RN)
             1 137102-65-9/BI
               (137102-65-9/RN)
             1 139691-92-2/BI
               (139691-92-2/RN)
             1 171049-35-7/BI
               (171049-35-7/RN)
             1 189161-35-1/BI
               (189161-35-1/RN)
             1 221049-79-2/BI
               (221049-79-2/RN)
             1 221049-80-5/BI
               (221049-80-5/RN)
             1 221049-81-6/BI
               (221049-81-6/RN)
             1 221049-82-7/BI
               (221049-82-7/RN)
             1 221049-83-8/BI
               (221049-83-8/RN)
             1 221049-84-9/BI
               (221049-84-9/RN)
             1 221049-85-0/BI
               (221049-85-0/RN)
             1 221049-86-1/BI
               (221049-86-1/RN)
             1 221049-87-2/BI
               (221049-87-2/RN)
             1 221049-88-3/BI
               (221049-88-3/RN)
             1 221049-89-4/BI
               (221049-89-4/RN)
             1 221049-90-7/BI
               (221049-90-7/RN)
             1 221049-91-8/BI
               (221049-91-8/RN)
             1 221049-92-9/BI
               (221049-92-9/RN)
             1 221049-93-0/BI
               (221049-93-0/RN)
             1 221049-94-1/BI
               (221049-94-1/RN)
             1 221049-95-2/BI
               (221049-95-2/RN)
             1 221049-96-3/BI
               (221049-96-3/RN)
             1 221049-97-4/BI
               (221049-97-4/RN)
             1 221049-98-5/BI
               (221049-98-5/RN)
             1 221049-99-6/BI
               (221049-99-6/RN)
             1 221050-00-6/BI
               (221050-00-6/RN)
```

1 221050-01-7/BI
(221050-01-7/RN)
1 221050-02-8/BI
(221050-02-8/RN)
1 221050-03-9/BI
(221050-03-9/RN)
1 221050-04-0/BI
(221050-04-0/RN)
1 221050-05-1/BI
(221050-05-1/RN)
1 221050-06-2/BI
(221050-06-2/RN)
1 221050-07-3/BI
(221050-07-3/RN)
1 221050-08-4/BI
(221050-08-4/RN)
1 221050-09-5/BI
(221050-09-5/RN)
1 221050-10-8/BI
(221050-10-8/RN)
1 221050-11-9/BI
(221050-11-9/RN)
1 221050-12-0/BI
(221050-12-0/RN)
1 221050-13-1/BI
(221050-13-1/RN)
1 221050-14-2/BI
(221050-14-2/RN)
1 221050-15-3/BI
(221050-15-3/RN)
1 221050-16-4/BI
(221050-16-4/RN)
1 221050-17-5/BI
(221050-17-5/RN)
1 221050-18-6/BI
(221050-18-6/RN)
1 221050-19-7/BI
(221050-19-7/RN)
1 221050-20-0/BI
(221050-20-0/RN)
1 221050-21-1/BI
(221050-21-1/RN)
1 221050-22-2/BI
(221050-22-2/RN)
1 221050-23-3/BI
(221050-23-3/RN)
1 221050-24-4/BI
(221050-24-4/RN)
1 221050-25-5/BI
(221050-25-5/RN)
1 221050-26-6/BI
(221050-26-6/RN)
1 221050-27-7/BI
(221050-27-7/RN)
1 221050-28-8/BI
(221050-28-8/RN)
1 221050-29-9/BI
(221050-29-9/RN)
1 221050-30-2/BI

(221050-30-2/RN)
1 221050-31-3/BI
(221050-31-3/RN)
1 221050-32-4/BI
(221050-32-4/RN)
1 221050-33-5/BI
(221050-33-5/RN)
1 221050-34-6/BI
(221050-34-6/RN)
1 221050-35-7/BI
(221050-35-7/RN)
1 221050-36-8/BI
(221050-36-8/RN)
1 221050-37-9/BI
(221050-37-9/RN)
1 221050-38-0/BI
(221050-38-0/RN)
1 221050-39-1/BI
(221050-39-1/RN)
1 221050-41-5/BI
(221050-41-5/RN)
1 221050-43-7/BI
(221050-43-7/RN)
1 221050-45-9/BI
(221050-45-9/RN)
1 221050-47-1/BI
(221050-47-1/RN)
1 221050-49-3/BI
(221050-49-3/RN)
1 221050-51-7/BI
(221050-51-7/RN)
1 221050-52-8/BI
(221050-52-8/RN)
1 221050-53-9/BI
(221050-53-9/RN)
1 221050-54-0/BI
(221050-54-0/RN)
1 221050-55-1/BI
(221050-55-1/RN)
1 221050-57-3/BI
(221050-57-3/RN)
1 221050-58-4/BI
(221050-58-4/RN)
1 221050-59-5/BI
(221050-59-5/RN)
1 221050-60-8/BI
(221050-60-8/RN)
1 221050-61-9/BI
(221050-61-9/RN)
1 221050-62-0/BI
(221050-62-0/RN)
1 221050-63-1/BI
(221050-63-1/RN)
1 221050-64-2/BI
(221050-64-2/RN)
1 221050-65-3/BI
(221050-65-3/RN)
1 221050-66-4/BI
(221050-66-4/RN)

1 221050-67-5/BI
(221050-67-5/RN)
1 221050-68-6/BI
(221050-68-6/RN)
1 221050-69-7/BI
(221050-69-7/RN)
1 221050-70-0/BI
(221050-70-0/RN)
1 221050-71-1/BI
(221050-71-1/RN)
1 221050-72-2/BI
(221050-72-2/RN)
1 221050-74-4/BI
(221050-74-4/RN)
1 221050-75-5/BI
(221050-75-5/RN)
1 221050-76-6/BI
(221050-76-6/RN)
1 221050-77-7/BI
(221050-77-7/RN)
1 221050-78-8/BI
(221050-78-8/RN)
1 221050-79-9/BI
(221050-79-9/RN)
1 221050-80-2/BI
(221050-80-2/RN)
1 221050-81-3/BI
(221050-81-3/RN)
1 221050-82-4/BI
(221050-82-4/RN)
1 221050-83-5/BI
(221050-83-5/RN)
1 221050-84-6/BI
(221050-84-6/RN)
1 221050-85-7/BI
(221050-85-7/RN)
1 221050-86-8/BI
(221050-86-8/RN)
1 221050-87-9/BI
(221050-87-9/RN)
1 221050-88-0/BI
(221050-88-0/RN)
1 221050-89-1/BI
(221050-89-1/RN)
1 221050-90-4/BI
(221050-90-4/RN)
1 221050-91-5/BI
(221050-91-5/RN)
1 221050-92-6/BI
(221050-92-6/RN)
1 221050-93-7/BI
(221050-93-7/RN)
1 221050-94-8/BI
(221050-94-8/RN)
1 221050-95-9/BI
(221050-95-9/RN)
1 221050-96-0/BI
(221050-96-0/RN)
1 221052-27-3/BI

(221052-27-3/RN)
1 221108-37-8/BI
(221108-37-8/RN)
1 285-67-6/BI
(285-67-6/RN)
1 350-46-9/BI
(350-46-9/RN)
1 3934-20-1/BI
(3934-20-1/RN)
1 5442-34-2/BI
(5442-34-2/RN)
1 5454-83-1/BI
(5454-83-1/RN)
1 57260-71-6/BI
(57260-71-6/RN)
1 611-71-2/BI
(611-71-2/RN)
1 622-58-2/BI
(622-58-2/RN)
1 70-11-1/BI
(70-11-1/RN)
1 703-59-3/BI
(703-59-3/RN)
1 78619-84-8/BI
(78619-84-8/RN)
1 85-44-9/BI
(85-44-9/RN)
1 88807-02-7/BI
(88807-02-7/RN)
1 89813-47-8/BI
(89813-47-8/RN)

L2 133 (102089-74-7/BI OR 104-84-7/BI OR 105-36-2/BI OR 137102-65-9/BI OR 139691-92-2/BI OR 171049-35-7/BI OR 189161-35-1/BI OR 221049-79-2/BI OR 221049-80-5/BI OR 221049-81-6/BI OR 221049-82-7/BI OR 221049-83-8/BI OR 221049-84-9/BI OR 221049-85-0/BI OR 221049-86-1/BI OR 221049-87-2/BI OR 221049-88-3/BI OR 221049-89-4/BI OR 221049-90-7/BI OR 221049-91-8/BI OR 221049-92-9/BI OR 221049-93-0/BI OR 221049-94-1/BI OR 221049-95-2/BI OR 221049-96-3/BI OR 221049-97-4/BI OR 221049-98-5/BI OR 221049-99-6/BI OR 221050-00-6/BI OR 221050-01-7/BI OR 221050-02-8/BI OR 221050-03-9/BI OR 221050-04-0/BI OR 221050-05-1/BI OR 221050-06-2/BI OR 221050-07-3/BI OR 221050-08-4/BI OR 221050-09-5/BI OR 221050-10-8/BI OR 221050-11-9/BI OR 221050-12-0/BI OR 221050-13-1/BI OR 221050-14-2/BI OR 221050-15-3/BI OR 221050-16-4/BI OR 221050-17-5/BI OR 221050-18-6/BI OR 221050-19-7/BI OR 221050-20-0/BI OR 221050-21-1/BI OR 221050-22-2/BI OR 221050-23-3/BI OR 221050-24-4/BI OR 221050-25-5/BI OR 221050-26-6/BI OR 2210

=> d scan

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Carbamic acid, [(1R)-2-(2-oxo-1-piperidinyl)-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI)
MF C18 H26 N2 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):132

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(2,4-difluorophenyl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C29 H26 F2 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxylic acid, 1-amino-, (1R)-2-[[(4-methylphenyl)methyl]amino]-2-oxo-1-phenylethyl ester (9CI)
MF C26 H23 N3 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN [4,4'-Bipiperidine]-1-acetic acid, 1'-[(2R)-[[(1-amino-7-isoquinolinyl)carbonyl]amino]phenylacetyl]- (9CI)
MF C30 H35 N5 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R,2R)-1-([4,4'-bipiperidin]-1-ylcarbonyl)-2-methylbutyl]- (9CI)
MF C26 H37 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(2,5-dimethylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)

MF C30 H31 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS. REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[1-(4-fluorophenyl)-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]- (9CI)
MF C28 H25 F2 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]ethyl]- (9CI)
MF C28 H26 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C28 H26 F N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[[(4-methylphenyl)methyl]amino]-2-oxo-1-(phenylmethyl)ethyl]- (9CI)
MF C27 H26 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Cyclopentanol, 2-azido-, (1R,2R)-rel- (9CI)
MF C5 H9 N3 O

Relative stereochemistry.



L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Acetic acid, bromo-, ethyl ester (6CI, 8CI, 9CI)
MF C4 H7 Br O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Carbamic acid, [(1R)-2-(1-oxo-2(1H)-isoquinolinyl)-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI)
MF C22 H24 N2 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-1-cyclohexyl-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]- (9CI)
MF C28 H33 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-1-cyclohexyl-2-[[(1S)-1-cyclohexylethyl]amino]-2-oxoethyl]-3,4-dihydro- (9CI)
MF C26 H38 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[1'-(2-amino-2-oxoethyl)[4,4'-bipiperidin]-1-yl]-2-oxo-1-phenylethyl]- (9CI)
MF C30 H36 N6 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[(4-methylbenzoyl)amino]-1-phenylethyl]- (9CI)
MF C26 H24 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-1-cyclohexyl-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI)
MF C27 H32 N6 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-1-cyclohexyl-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]- (9CI)
MF C28 H32 F N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[(2,3-dihydro-1H-inden-1-yl)amino]-2-oxo-1-phenylethyl]- (9CI)
MF C27 H24 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(2-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C28 H26 Cl N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-(4-benzoyl-1-piperidinyl)-2-oxo-1-phenylethyl]- (9CI)
MF C30 H28 N4 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl) 2-(phenylmethyl) ester, (2S,4R)- (9CI)
MF C17 H23 N O5

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 6-Oxabicyclo[3.1.0]hexane (6CI, 7CI, 8CI, 9CI)
MF C5 H8 O
CI COM, RPS

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-1-cyclohexyl-2-[[(1S)-1-cyclohexylethyl]amino]-2-oxoethyl]-, mono(trifluoroacetate) (9CI)
MF C26 H36 N4 O2 . C2 H F3 O2

CM 1

Absolute stereochemistry.



CM 2



L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxylic acid, 1-amino-, mono(trifluoroacetate) (9CI)
MF C10 H8 N2 O2 . C2 H F3 O2

CM 1



CM 2



L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazole-3-methanamine, .alpha.-phenyl-5-(phenylmethyl)-, (.alpha.R)- (9CI)
MF C16 H16 N4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl]- (9CI)
MF C29 H35 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[(4-methoxybenzoyl)amino]-1-phenylethyl]- (9CI)
MF C26 H24 N4 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-(4-phenyl-1-piperidinyl)ethyl]- (9CI)
MF C29 H28 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(3-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C28 H26 Cl N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[(1,2,3,4-tetrahydro-1-isoquinolinyl)amino]ethyl]- (9CI)
MF C27 H25 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (9CI)
MF C26 H25 N7 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI)
MF C27 H26 N6 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Carbamic acid, [(1R)-2-hydroxy-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI)
MF C13 H19 N O3

Absolute stereochemistry. Rotation (-).





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Benzene, 1-fluoro-4-nitro- (8CI, 9CI)
MF C6 H4 F N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Benzeneacetic acid, .alpha.-amino-, hydrazide, (.alpha.R)- (9CI)
MF C8 H11 N3 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Benzamide, N-[(2R)-2-amino-2-phenylethyl]-4-methyl- (9CI)
MF C16 H18 N2 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 2-Thiazolemethanamine, .alpha.,4-diphenyl-, (.alpha.R)- (9CI)
MF C16 H14 N2 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Carbamic acid, (4-methylphenyl)-, (2R)-2-[[(1-amino-7-isoquinolinyl)carbonyl]amino]-2-phenylethyl ester (9CI)
MF C26 H24 N4 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-(benzoylamino)-1-phenylethyl]-(9CI)
MF C25 H22 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]- (9CI)
MF C30 H30 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(3-methylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C29 H29 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[[3-[(3-aminophenyl)methyl]phenyl]amino]-2-oxo-1-phenylethyl]- (9CI)
MF C31 H27 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-(1-piperidinyl)ethyl]- (9CI)
MF C23 H24 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-aminophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C28 H28 N6 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Carbamic acid, [(1R)-2-amino-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI)
MF C13 H20 N2 O2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Benzeneacetic acid, .alpha.-hydroxy-, (.alpha.R)- (9CI)
MF C8 H8 O3
CI COM

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Carbamic acid, [(1R)-2-amino-1-phenyl-2-thioxoethyl]-, 1,1-dimethylethyl ester (9CI)
MF C13 H18 N2 O2 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN [4,4'-Bipiperidine]-1-carboxylic acid, 1'-[(2R)-phenyl[[(phenylmethoxy)carbonyl]amino]acetyl]-, 1,1-dimethylethyl ester (9CI)
MF C31 H41 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxylic acid, 1-amino- (9CI)
MF C10 H8 N2 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[[2-(4-aminophenoxy)cyclopentyl]amino]-2-oxo-1-phenylethyl]- (9CI)
MF C29 H29 N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-1-phenyl-2-[(phenylacetyl)amino]ethyl]- (9CI)
MF C26 H24 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4,4'-bipiperidin]-1-yl-2-oxo-1-phenylethyl]- (9CI)
MF C28 H33 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(3-methoxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C29 H29 N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, N-[(1R)-2-[(3-acetylphenyl)amino]-2-oxo-1-phenylethyl]-1-amino- (9CI)
MF C26 H22 N4 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]- (9CI)
MF C28 H27 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-(4-phenyl-1-piperazinyl)ethyl]- (9CI)
MF C28 H27 N5 O2

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Proteinase inhibitor, serine (9CI)
MF Unspecified
CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Benzene, 1-isocyanato-4-methyl- (9CI)
MF C8 H7 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Carbamic acid, [(R)-phenyl(4-phenyl-2-thiazolyl)methyl]-,
1,1-dimethylethyl ester (9CI)
MF C21 H22 N2 O2 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Carbamic acid, [(1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-

phenylethyl]-, phenylmethyl ester (9CI)
MF C27 H35 N3 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxylic acid, 1-amino-, ethyl ester, monohydrochloride (9CI)
MF C12 H12 N2 O2 . Cl H



● HCl

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN L-Proline, (2R)-N-[(1-amino-7-isoquinolinyl)carbonyl]-2-phenylglycyl-4-phenoxy-, (4S)- (9CI)
MF C29 H26 N4 O5

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-1-phenyl-2-[(phenylsulfonyl)amino]ethyl]- (9CI)
MF C24 H22 N4 O3 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-1-cyclohexyl-2-[[(1S)-1-cyclohexylethyl]amino]-2-oxoethyl]- (9CI)
MF C26 H36 N4 O2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(2-fluorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C28 H26 F N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[[3-(1-hydroxyethyl)phenyl]amino]-2-oxo-1-phenylethyl]- (9CI)
MF C26 H24 N4 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-2-(4-phenoxy-1-piperidinyl)-1-phenylethyl]- (9CI)
MF C29 H28 N4 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]- (9CI)
MF C27 H26 N6 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN [4,4'-Bipiperidine]-1-carboxylic acid, 1,1-dimethylethyl ester (9CI)
MF C15 H28 N2 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-2-Benzopyran-1,3(4H)-dione (9CI)

MF C9 H6 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxylic acid (9CI)
MF C10 H7 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 4,4'-Bipiperidine, 1-[(2R)-aminophenylacetyl]-1'-methyl- (9CI)
MF C19 H29 N3 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxylic acid, 1-[(phenylmethyl)amino]-, ethyl ester, mono(trifluoroacetate) (9CI)
MF C19 H18 N2 O2 . C2 H F3 O2

CM 1



CM 2



L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyrimidinyl)-1-piperazinyl]ethyl]- (9CI)
MF C26 H25 N7 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[(cyclohexylcarbonyl)amino]-1-phenylethyl]- (9CI)
MF C25 H28 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[2-[4,4'-bipiperidin]-1-yl-2-oxo-1-(2-thienyl)ethyl]- (9CI)
MF C26 H31 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(2-hydroxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C28 H27 N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C28 H26 Cl N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[(2-methylcyclohexyl)amino]-2-oxo-1-phenylethyl]- (9CI)
MF C25 H28 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (9CI)
MF C27 H26 N6 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Carbamic acid, [(1R)-2-amino-2-oxo-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI)
MF C13 H18 N2 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Pyrimidine, 2,4-dichloro- (7CI, 8CI, 9CI)
MF C4 H2 Cl2 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[1,4'-bipiperidin]-1'-yl-2-oxo-1-phenylethyl]- (9CI)
MF C28 H33 N5 O2

Absolute stereochemistry.



proviso

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2   133 ANSWERS   REGISTRY   COPYRIGHT 2003 ACS on STN
IN   Benzene, 1-[[(1R,2R)-2-azidocyclopentyl]oxy]-4-nitro-, rel- (9CI)
MF   C11 H12 N4 O3

Relative stereochemistry.



L2   133 ANSWERS   REGISTRY   COPYRIGHT 2003 ACS on STN
IN   7-Isoquinolinecarboxylic acid, 1-amino-3,4-dihydro-, ethyl ester (9CI)
MF   C12 H14 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2   133 ANSWERS   REGISTRY   COPYRIGHT 2003 ACS on STN
IN   7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-(2-oxo-1-piperidinyl)-1-
     phenylethyl]- (9CI)
MF   C23 H24 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[(cyclohexylacetyl)amino]-1-phenylethyl]- (9CI)
MF C26 H30 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[2-[4,4'-bipiperidin]-1-yl-1-(1-naphthalenyl)-2-oxoethyl]- (9CI)
MF C32 H35 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(2,4-difluorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C28 H25 F2 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-hydroxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C28 H27 N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[[(1S)-1-cyclohexylethyl]amino]-2-oxo-1-phenylethyl]- (9CI)

MF C26 H30 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]- (9CI)
MF C29 H26 F3 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Glycine, (2R)-N-[(1-amino-7-isoquinolinyl)carbonyl]-2-phenylglycyl-3-(2-naphthalenyl)-D-alanyl- (9CI)
MF C33 H29 N5 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Benzeneethanimidic acid, ethyl ester, hydrochloride (9CI)
MF C10 H13 N O . Cl H



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[[[4-(aminomethyl)cyclohexyl]methyl]amino]-2-oxo-1-phenylethyl]- (9CI)
MF C26 H31 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1,2-Pyrrolidinedicarboxylic acid, 4-phenoxy-, 1-(1,1-dimethylethyl) 2-(phenylmethyl) ester, (2S,4S)- (9CI)
MF C23 H27 N O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinemethanol, 1-amino- (9CI)
MF C10 H10 N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-(1-oxo-2(1H)-isoquinolinyl)-1-phenylethyl]- (9CI)
MF C27 H22 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN [4,4'-Bipiperidine]-1-acetic acid, 1'-[(2R)-[[(1-amino-7-

isoquinolinyl)carbonyl]amino]phenylacetyl]-, ethyl ester (9CI)
MF C32 H39 N5 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4,4'-bipiperidin]-1-yl-1-cyclohexyl-2-oxoethyl]- (9CI)
MF C28 H39 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(2,3-dimethylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C30 H31 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-nitrophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C28 H26 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[[(4-methoxyphenyl)methyl]amino]-2-oxo-1-phenylethyl]- (9CI)
MF C26 H24 N4 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C29 H29 N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN D-Proline, (2R)-N-[(1-amino-7-isoquinolinyl)carbonyl]-2-phenylglycyl-3-(2-naphthalenyl)-D-alanyl- (9CI)
MF C36 H33 N5 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Pentanoic acid, 5-bromo-, methyl ester (9CI)
MF C6 H11 Br O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Ethanone, 2-bromo-1-phenyl- (9CI)
MF C8 H7 Br O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1-Piperazinecarboxylic acid, 4-(2-chloro-4-pyrimidinyl)-, 1,1-dimethylethyl ester (9CI)
MF C13 H19 Cl N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1-Isoquinolinamine, 7-(bromomethyl)- (9CI)
MF C10 H9 Br N2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-phenylethyl]- (9CI)
MF C26 H20 N4 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-(1'-ethyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl]- (9CI)
MF C30 H37 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1S)-2-[4,4'-bipiperidin]-1-yl-2-oxo-1-phenylethyl]- (9CI)
MF C28 H33 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(2,4-dimethylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C30 H31 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS. REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-methylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C29 H29 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[(1,3-benzodioxol-5-ylmethyl)amino]-2-oxo-1-phenylethyl]- (9CI)
MF C26 H22 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(2-methylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C29 H29 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN D-Alaninamide, (2R)-N-[(1-amino-7-isoquinolinyl)carbonyl]-2-phenylglycyl-3-(2-naphthalenyl)- (9CI)
MF C31 H27 N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1-Piperazinecarboxylic acid, 1,1-dimethylethyl ester (9CI)
MF C9 H18 N2 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1,3-Isobenzofurandione (9CI)
MF C8 H4 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1-Piperazinecarboxylic acid, 4-(4-pyrimidinyl)-, 1,1-dimethylethyl ester (9CI)
MF C13 H20 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN L-Proline, (2R)-N-[(1-amino-7-isoquinolinyl)carbonyl]-2-phenylglycyl-3-(2-naphthalenyl)-D-alanyl- (9CI)
MF C36 H33 N5 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Benzoic acid, 4-methyl-, (2R)-2-[[(1-amino-7-isoquinolinyl)carbonyl]amino]-2-phenylethyl ester (9CI)
MF C26 H23 N3 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-(1'-propyl[4,4'-bipiperidin]-1-yl)ethyl]- (9CI)
MF C31 H39 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[2-[4,4'-bipiperidin]-1-yl-1-(3-chlorophenyl)-2-oxoethyl]- (9CI)
MF C28 H32 Cl N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(2,6-dimethylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C30 H31 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-methoxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C29 H29 N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-(1-naphthalenylamino)-2-oxo-1-phenylethyl]- (9CI)
MF C28 H22 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI)
MF C30 H29 N5 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7-Isoquinolinecarboxamide, 1-amino-N-[(1R)-2-[[(4-methylphenyl)methyl]amino]-2-oxo-1-phenylethyl]- (9CI)
MF C26 H24 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 4,4'-Bipiperidine, dihydrochloride (9CI)
MF C10 H20 N2 . 2 Cl H



2 HCl

L2 133 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Benzenemethanamine, 4-methyl- (9CI)
MF C8 H11 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED